Deutsche Märkte geschlossen
DAX
17.896,50 -35,67 (-0,20%) Euro Stoxx 50
4.890,61 -30,61 (-0,62%) Dow Jones 30
38.088,44 +185,15 (+0,49%) Gold
2.308,00 -3,00 (-0,13%) EUR/USD
1,0709 -0,0009 (-0,09%) Bitcoin EUR
55.354,28 +2.287,16 (+4,31%)
Lexaria Bioscience Corp. (LEXX)
NasdaqCM - NasdaqCM Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
Ab 12:01PM EDT. Markt geöffnet.
| Kurs Vortag | 3,4900 |
| Öffnen | 3,5000 |
| Gebot | 3,0500 x 100 |
| Briefkurs | 3,1400 x 100 |
| Tagesspanne | 2,9500 - 3,5300 |
| 52-Wochen-Spanne | 0,6490 - 6,8500 |
| Volumen | |
| Durchschn. Volumen | 515.409 |
| Marktkap. | 39,624M |
| Beta (5 J., monatlich) | 0,95 |
| Kurs-Gewinn-Verhältnis (roll. Hochrechn.) | N/A |
| EPS (roll. Hochrechn.) | -0,6700 |
| Gewinndatum | 12. Juli 2024 - 16. Juli 2024 |
| Erwartete Dividende & Rendite | N/A (N/A) |
| Ex-Dividendendatum | N/A |
| 1-Jahres-Kursziel | 10,00 |
ACCESSWIRELexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces its intention to launch new human and animal studies to examine DehydraTECH™-processed glucagon-like peptide-1 ("GLP-1") drugs such as, but not limited to, semaglutide sold under Novo Nordisk's brand names Ozempic®, Wegovy® and Rybelsus®, for purposes of improved bioavailability, cost-effectiveness, tolerability,
